On the public citation graph
Antibody–Drug Conjugate Payloads; Study of Auristatin Derivatives
0 signed · 141 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/anie.201307628openalex-snapshot
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
inferredcites →https://doi.org/10.1002/cncr.22334openalex-snapshot
Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy
inferredcites →https://doi.org/10.1002/pros.23226openalex-snapshot
Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth
inferredcites →https://doi.org/10.1007/s10637-005-2909-xopenalex-snapshot
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers
inferredcites →https://doi.org/10.1007/s10637-005-6735-yopenalex-snapshot
Phase II trial of dolastatin-10 in patients with advanced breast cancer
inferredcites →https://doi.org/10.1007/s10928-016-9495-8openalex-snapshot
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
inferredcites →https://doi.org/10.1016/0006-2952(90)90367-topenalex-snapshot
Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10
inferredcites →https://doi.org/10.1016/0006-2952(90)90613-popenalex-snapshot
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal
inferredcites →https://doi.org/10.1016/0006-2952(93)90051-wopenalex-snapshot
Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin
inferredcites →https://doi.org/10.1016/0040-4020(93)80003-copenalex-snapshot
Isolation of dolastatins 10–15 from the marine mollusc
inferredcites →https://doi.org/10.1016/0306-3623(93)90385-bopenalex-snapshot
Antibodies as carriers of cytotoxicity
inferredcites →https://doi.org/10.1016/j.drudis.2017.05.011openalex-snapshot
Advances in antibody–drug conjugates: A new era of targeted cancer therapy
inferredcites →https://doi.org/10.1016/j.jddst.2018.08.022openalex-snapshot
Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview
inferredcites →https://doi.org/10.1016/s0021-9258(17)44880-0openalex-snapshot
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
inferredcites →https://doi.org/10.1016/s0041-0101(97)00074-3openalex-snapshot
Toxins of Amanita phalloides
inferredcites →https://doi.org/10.1016/s0090-8258(03)00007-6openalex-snapshot
A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study
inferredcites →https://doi.org/10.1021/acs.bioconjchem.5b00603openalex-snapshot
Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation
inferredcites →https://doi.org/10.1021/acs.bioconjchem.6b00530openalex-snapshot
Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates
inferredcites →https://doi.org/10.1021/acs.jnatprod.7b00359openalex-snapshot
Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains
inferredcites →https://doi.org/10.1021/acs.molpharmaceut.6b00082openalex-snapshot
Increment in Drug Loading on an Antibody–Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro
inferredcites →https://doi.org/10.1021/acs.molpharmaceut.8b00225openalex-snapshot
Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite
inferredcites →https://doi.org/10.1021/acsomega.8b00093openalex-snapshot
Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications
inferredcites →https://doi.org/10.1021/bc025536jopenalex-snapshot
Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity
inferredcites →https://doi.org/10.1021/bc0502917openalex-snapshot
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
inferredcites →https://doi.org/10.1021/bc300491kopenalex-snapshot
Total Antibody Quantification for MMAE-Conjugated Antibody–Drug Conjugates: Impact of Assay Format and Reagents
inferredcites →https://doi.org/10.1021/bc400439xopenalex-snapshot
Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload
inferredcites →https://doi.org/10.1021/bc700321zopenalex-snapshot
Selection of Reaction Additives Used in the Preparation of Monomeric Antibody−Calicheamicin Conjugates
inferredcites →https://doi.org/10.1021/bc9001097openalex-snapshot
Design, Synthesis, and Biological Evaluation of Antibody−Drug Conjugates Comprised of Potent Camptothecin Analogues
inferredcites →https://doi.org/10.1021/cr200409fopenalex-snapshot
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
inferredcites →https://doi.org/10.1021/ja00195a084openalex-snapshot
Antineoplastic agent. 174. Isolation and structure of the cytostatic depsipeptide dolastatin 13 from the sea hare Dolabella auricularia
inferredcites →https://doi.org/10.1021/ja00256a070openalex-snapshot
The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10
inferredcites →https://doi.org/10.1021/ja00258a081openalex-snapshot
Antineoplastic agents. 150. The structure and synthesis of dolastatin 3
inferredcites →https://doi.org/10.1021/ja00367a067openalex-snapshot
Antineoplastic agents. 3. Structure of the cyclic peptide dolastatin 3 from Dolabella auricularia
inferredcites →https://doi.org/10.1021/jm020149gopenalex-snapshot
Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains
inferredcites →https://doi.org/10.1021/jm3009629openalex-snapshot
A Synthetic Dolastatin 10 Analogue Suppresses Microtubule Dynamics, Inhibits Cell Proliferation, and Induces Apoptotic Cell Death
inferredcites →https://doi.org/10.1021/jm501649kopenalex-snapshot
Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
inferredcites →https://doi.org/10.1021/jo00287a003openalex-snapshot
Isolation and structure of the cytostatic linear depsipeptide dolastatin 15
inferredcites →https://doi.org/10.1021/jo00297a001openalex-snapshot
Antineoplastic agents. 190. Isolation and structure of the cyclodepsipeptide dolastatin 14
inferredcites →https://doi.org/10.1021/mp500762uopenalex-snapshot
Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates
inferredcites →https://doi.org/10.1021/np50016a016openalex-snapshot
Marine Animal Biosynthetic Constituents For Cancer Chemotherapy
inferredcites →https://doi.org/10.1023/a:1008349209956openalex-snapshot
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer
inferredcites →https://doi.org/10.1023/a:1010626230081openalex-snapshot
Dolastatin-10 in Metastatic Melanoma: A Phase II and Pharmokinetic Trial of the California Cancer Consortium
inferredcites →https://doi.org/10.1038/nbt.2289openalex-snapshot
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
inferredcites →https://doi.org/10.1038/nbt.3212openalex-snapshot
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
inferredcites →https://doi.org/10.1038/nbt832openalex-snapshot
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
inferredcites →https://doi.org/10.1039/9781788012898openalex-snapshot
Cytotoxic Payloads for Antibody – Drug Conjugates
inferredcites →https://doi.org/10.1056/nejmoa1209124openalex-snapshot
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
inferredcites →https://doi.org/10.1080/19420862.2018.1556465openalex-snapshot
Antibodies to watch in 2019
inferredcites →https://doi.org/10.1093/jnci/djs140openalex-snapshot
Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma
inferredcites →https://doi.org/10.1097/00000421-200210000-00005openalex-snapshot
Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer
inferredcites →https://doi.org/10.1111/j.1349-7006.1997.tb00383.xopenalex-snapshot
Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 Derivative
inferredcites →https://doi.org/10.1155/2004/924913openalex-snapshot
Phase II Trial of Dolastatin‐10, a Novel Anti‐Tubulin Agent, in Metastatic Soft Tissue Sarcomas
inferredcites →https://doi.org/10.1158/0008-5472.can-15-1313openalex-snapshot
Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-0789openalex-snapshot
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-0486openalex-snapshot
Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-0762openalex-snapshot
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-16-0184openalex-snapshot
A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
inferredcites →https://doi.org/10.1159/isbn.978-3-318-03426-4openalex-snapshot
Antibodies as Carriers of Cytotoxicity
inferredcites →https://doi.org/10.1201/9781420039658openalex-snapshot
Anticancer Agents from Natural Products
inferredcites →https://doi.org/10.1248/cpb.43.1706openalex-snapshot
Synthesis and Antitumor Activity of Novel Dolastatin 10 Analogs.
inferredcites →https://doi.org/10.1248/cpb.c18-00744openalex-snapshot
The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
inferredcites →https://doi.org/10.3109/10428199209064902openalex-snapshot
Cytostatic Effects of Dolastatin 10 and Dolastatin 15 on Human Leukemia Cell Lines
inferredcites →https://doi.org/10.3987/com-88-s33openalex-snapshot
Isolation and Structure of the Cell Growth Inhibitory Depsipeptides Dolastatins 11 and 12
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/cbdv.202402113openalex-snapshot
Antibody Modification via Lipoic Acid Ligase A‐Mediated Site‐Specific Labeling
inferred← citeshttps://doi.org/10.1002/cmdc.202300720openalex-snapshot
Small Molecule‐Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs
inferred← citeshttps://doi.org/10.1002/cmdc.202500580openalex-snapshot
Exploration of the Tertiary Amide Chemical Space of Dolastatin 15 Analogs Reveals New Insights into the Structure–Anticancer Activity Relationship
inferred← citeshttps://doi.org/10.1002/jssc.202100575openalex-snapshot
Current approaches for the purification of antibody–drug conjugates
inferred← citeshttps://doi.org/10.1002/mog2.78openalex-snapshot
VISTA‐targeted antibody‐drug conjugates exhibit potent antitumor effects on malignant pleural mesothelioma
inferred← citeshttps://doi.org/10.1002/psc.3561openalex-snapshot
Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment
inferred← citeshttps://doi.org/10.1002/slct.202302947openalex-snapshot
Lipoic Acid Ligase A‐Mediated Ligation: Mechanism, Applications, and Emerging Innovations in Bioconjugation
inferred← citeshttps://doi.org/10.1007/s10311-024-01720-8openalex-snapshot
The chemical basis of seawater therapies: a review
inferred← citeshttps://doi.org/10.1007/s11095-023-03649-zopenalex-snapshot
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
inferred← citeshttps://doi.org/10.1007/s11912-024-01576-9openalex-snapshot
Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review
inferred← citeshttps://doi.org/10.1007/s12032-023-02168-6openalex-snapshot
Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine
inferred← citeshttps://doi.org/10.1007/s12272-026-01595-zopenalex-snapshot
Bispecific antibody–drug conjugates: a modular blueprint for next-generation cancer therapeutics
inferred← citeshttps://doi.org/10.1007/s12672-024-01509-9openalex-snapshot
Polymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy
inferred← citeshttps://doi.org/10.1007/s12672-025-02362-0openalex-snapshot
Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study
inferred← citeshttps://doi.org/10.1007/s43450-023-00384-9openalex-snapshot
Current Prospects and Clinical Status of Microalgae Derived Chemotherapeutics
inferred← citeshttps://doi.org/10.1016/b978-0-323-85704-8.00024-4openalex-snapshot
Preclinical Development of Antibody–Drug Conjugates
inferred← citeshttps://doi.org/10.1016/b978-0-323-91668-4.00007-1openalex-snapshot
Site-specific drug delivery utilizing monoclonal antibodies
inferred← citeshttps://doi.org/10.1016/bs.coac.2023.02.007openalex-snapshot
Antibody-drug conjugates for cancer therapy: An up-to-date review on the chemistry and pharmacology
inferred← citeshttps://doi.org/10.1016/j.apsb.2023.06.015openalex-snapshot
Antibody–drug conjugates: Recent advances in payloads
inferred← citeshttps://doi.org/10.1016/j.bbrc.2023.149214openalex-snapshot
An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment
inferred← citeshttps://doi.org/10.1016/j.biochi.2025.10.003openalex-snapshot
Bispecific targeting system based on DARPins-modified light-chain ferritin for cancer chemotherapy
inferred← citeshttps://doi.org/10.1016/j.bmc.2026.118674openalex-snapshot
Peptide–drug conjugates bearing an antimitotic Ahx-DA1 payload achieve potent antitumor activity in Her2-amplified and EGFR-positive KRAS-mutant cancers in vivo
inferred← citeshttps://doi.org/10.1016/j.bmcl.2023.129573openalex-snapshot
PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers
inferred← citeshttps://doi.org/10.1016/j.bmcl.2024.130085openalex-snapshot
Design, synthesis and biological evaluation of camptothecin analogue FL118 as a payload for antibody-drug conjugates in targeted cancer therapy
inferred← citeshttps://doi.org/10.1016/j.drudis.2021.06.012openalex-snapshot
Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.118482openalex-snapshot
Recent advances in peptide-drug conjugates as anticancer agents
inferred← citeshttps://doi.org/10.1016/j.isci.2023.107778openalex-snapshot
Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2021.107917openalex-snapshot
Stepping forward in antibody-drug conjugate development
inferred← citeshttps://doi.org/10.1016/j.phrs.2024.107341openalex-snapshot
Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions
inferred← citeshttps://doi.org/10.1016/j.yrtph.2025.105974openalex-snapshot
Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugates
inferred← citeshttps://doi.org/10.1021/acs.bioconjchem.3c00374openalex-snapshot
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
inferred← citeshttps://doi.org/10.1021/acs.jnatprod.5c00439openalex-snapshot
In Silico Design and Analysis of Cyanobacterial Pseudo Natural Products
inferred← citeshttps://doi.org/10.1021/acs.oprd.4c00318openalex-snapshot
Process Development for the First GMP Synthesis of SGD-9501-TFA, Part 2: Synthesis of the Payload, Linker, and Drug Linker
inferred← citeshttps://doi.org/10.1021/acschembio.6c00539openalex-snapshot
Modular Assembly of Systems for Antibody-Directed Enzyme Prodrug Therapy
inferred← citeshttps://doi.org/10.1021/acsomega.5c03755openalex-snapshot
Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms
inferred← citeshttps://doi.org/10.1038/s41419-024-06837-wopenalex-snapshot
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies
inferred← citeshttps://doi.org/10.1038/s41419-025-07758-yopenalex-snapshot
Loss of RNF41 promotes bladder cancer metastasis through increasing NUDC stability to enhance tubulin polymerization
inferred← citeshttps://doi.org/10.1038/s41587-025-02772-zopenalex-snapshot
Antibody–bottlebrush prodrug conjugates for targeted cancer therapy
inferred← citeshttps://doi.org/10.1038/s42004-026-01886-yopenalex-snapshot
Identification of an αvβ3-targeting bicyclic peptide with atypical norArg-Gly-Asp sequence
inferred← citeshttps://doi.org/10.1039/d5md00740bopenalex-snapshot
An overview of recent advancements in targeted cancer therapies and their potential clinical impact
inferred← citeshttps://doi.org/10.1080/00498254.2024.2340741openalex-snapshot
A modelling approach to compare ADC deconjugation and systemic elimination rates of individual drug-load species using native ADC LC-MS data from human plasma
inferred← citeshttps://doi.org/10.1080/00498254.2024.2345849openalex-snapshot
Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species
inferred← citeshttps://doi.org/10.1080/00498254.2024.2381139openalex-snapshot
Beyond cytotoxic potency: disposition features required to design ADC payload
inferred← citeshttps://doi.org/10.1080/14712598.2021.1846714openalex-snapshot
An overview of process development for antibody-drug conjugates produced by chemical conjugation technology
inferred← citeshttps://doi.org/10.1080/14712598.2023.2276873openalex-snapshot
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry
inferred← citeshttps://doi.org/10.1093/abt/tbab026openalex-snapshot
Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer
inferred← citeshttps://doi.org/10.1093/abt/tbac001openalex-snapshot
Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
inferred← citeshttps://doi.org/10.1093/cvr/cvaf095openalex-snapshot
Adverse cardiac events associated with antibody-drug conjugates in cancer patients: retrospective analysis of FAERS database and RCTs
inferred← citeshttps://doi.org/10.1101/2021.07.07.451518openalex-snapshot
Anti-tumor efficacy of an MMAE conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer
inferred← citeshttps://doi.org/10.1158/1535-7163.mct-20-0618openalex-snapshot
Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models
inferred← citeshttps://doi.org/10.1158/1535-7163.mct-22-0160openalex-snapshot
Modular Smart Molecules for PSMA-Targeted Chemotherapy
inferred← citeshttps://doi.org/10.1158/2767-9764.crc-25-0381openalex-snapshot
Targeting uPARAP with an Antibody–Drug Conjugate Exhibits Efficacy against Mesothelioma and Synergizes with Cisplatin
inferred← citeshttps://doi.org/10.1186/s13046-025-03519-zopenalex-snapshot
Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
inferred← citeshttps://doi.org/10.1186/s41120-026-00161-7openalex-snapshot
Stabilization of Antibody Drug Conjugate (ADC) products by lyophilization: a review
inferred← citeshttps://doi.org/10.1200/edbk_433330openalex-snapshot
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy
inferred← citeshttps://doi.org/10.14229/jadc.2025.01.08.003openalex-snapshot
Araris Biotech and Chugai Pharmaceuticals to Develop Next-Generation Tailor-made ADCs
inferred← citeshttps://doi.org/10.2174/1389557523666230220121648openalex-snapshot
The Recent Developments of ADCs with the Tubulysins as the Payloads
inferred← citeshttps://doi.org/10.2174/1568009622666220224110538openalex-snapshot
Antibody-drug Conjugate Targets, Drugs, and Linkers
inferred← citeshttps://doi.org/10.26896/1028-6861-2026-92-7-13-18openalex-snapshot
Development and validation of a HPLC method for the determination of free emtansine impurity in a therapeutic conjugate based on a recombinant targeted protein molecule
inferred← citeshttps://doi.org/10.3389/fcell.2025.1669592openalex-snapshot
Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs
inferred← citeshttps://doi.org/10.3389/fchem.2022.869639openalex-snapshot
Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin αVβ3
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1698458openalex-snapshot
Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review
inferred← citeshttps://doi.org/10.3390/cancers15061845openalex-snapshot
Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
inferred← citeshttps://doi.org/10.3390/cancers17020318openalex-snapshot
Unlocking the Therapeutic Potential of Algae-Derived Compounds in Hematological Malignancies
inferred← citeshttps://doi.org/10.3390/ijms23158219openalex-snapshot
Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression
inferred← citeshttps://doi.org/10.3390/ijms24108543openalex-snapshot
Old Drug, New Delivery Strategy: MMAE Repackaged
inferred← citeshttps://doi.org/10.3390/md19060342openalex-snapshot
Development of Marine-Derived Compounds for Cancer Therapy
inferred← citeshttps://doi.org/10.3390/md21010024openalex-snapshot
Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets
inferred← citeshttps://doi.org/10.3390/md23060233openalex-snapshot
Cyanobacterial Peptides in Anticancer Therapy: A Comprehensive Review of Mechanisms, Clinical Advances, and Biotechnological Innovation
inferred← citeshttps://doi.org/10.3390/molecules25092197openalex-snapshot
Marine Cyanobacteria: A Source of Lead Compounds and their Clinically-Relevant Molecular Targets
inferred← citeshttps://doi.org/10.3390/molecules26102943openalex-snapshot
Antibody–Drug Conjugates—A Tutorial Review
inferred← citeshttps://doi.org/10.3390/pharmaceutics15082160openalex-snapshot
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
inferred← citeshttps://doi.org/10.37349/etat.2021.00064openalex-snapshot
Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
inferred← citeshttps://doi.org/10.37349/etat.2022.00077openalex-snapshot
Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
inferred← citeshttps://doi.org/10.7841/ksbbj.2025.40.1.22openalex-snapshot
Development of Monoclonal Antibody Application in Cancer Therapy: The Roles of ADCC, CDC, ADCP, and ADC
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.